Research Coverage on Small and Micro-Cap Companies, Zacks Small Cap Research

Zacks Small Cap Research

Zacks Small Cap Research provides research coverage on small- and micro-cap companies that are “under-followed” or “under-valued” by Wall Street. We produce high quality equity research for the institutional and retail investor on microcap firms we believe are well positioned for future growth. The Zacks SCR analyst team has an average of 20 years of experience in investment research. We conduct significant due diligence in an effort to maintain the highest quality small-cap universe.

Research Coverage on Small and Micro-Cap Companies

Equity Bottom-Up

<ul><li>On July 31, 2025, FibroBiologics, Inc. (FBLG) announced financial results for the second quarter of 2025 and provided a business update.</li><li>The company recently closed on the third tranche of $5M from a $25M total financing, which will be used to support the upcoming Phase 1/2 clinical trial in diabetic foot ulcers (DFUs).</li><li>That trial is expected to initiate in the first quarter of 2026 and complete in the third quarter of 2026.</li></ul>

On July 31, 2025, FibroBiologics, Inc. (FBLG) announced financial results for the second quarter of 2025 and provided a business update.The company recently closed on the third tranche of $5M from a $25M total financing, which will be used to support the upcoming Phase 1/2 clinical trial in diabetic foot ulcers (DFUs).That trial is expected to initiate in the first quarter of 2026 and complete in the third quarter of 2026.

FibroBiologics

FBLG: Closes Third Tranche of 5M